Kevin Tang - 21 Feb 2025 Form 4 Insider Report for Singular Genomics Systems, Inc.

Role
10%+ Owner
Signature
Kevin Tang
Issuer symbol
N/A
Transactions as of
21 Feb 2025
Net transactions value
$0
Form type
4
Filing time
27 Feb 2025, 20:54:47 UTC
Previous filing
09 Dec 2024
Next filing
04 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OMIC Common Stock Disposed to Issuer -372,000 -100% 0 21 Feb 2025 By LP F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Kevin Tang is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the "Issuer"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings.
F2 The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.